Medtronic Study of Affera Sphere-9 Catheter Meets Endpoints
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week.While there are several ETFs that provid
Pfizer "Disappointed" About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appeal Decision By European Patent Office
Pfizer "Disappointed" About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appe
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Moderna Vaccine Patent Upheld by European Patent Office: Report
Moderna Says European Patent Office Decided To Maintain Validity Of Co's EP949 Patent, One Of The Key Patents Currently Asserted Against Pfizer & BioNTech In Various European National Courts
Moderna Says European Patent Office Decided To Maintain Validity Of Co's EP949 Patent, One Of The Key Patents Currently Asserted Against Pfizer & BioNTech In Various European National Courts
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandem
Dividend Roundup: Home Depot, Alibaba, Johnson & Johnson, Yum! Brands, and More
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this
Check Out What Whales Are Doing With MRK
Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Viking Falls After Roche's Obesity Drug Data
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.
Johnson & Johnson Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 14.07% RBC Capital → $175 Reiterates Outperform → Outperform 05/06/2024 40.15% Cantor Fitzgeral
GSK to Sell Entire Haleon Stake
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Eli Lilly and Co (NYSE:LLY) released Thursday topline results from two phase 3 trials. The drugmaker evaluated once-weekly insulin efsitora alfa (efsitora) in type 2 diabetes patients using insulin fo
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Top Institutions' Q1 US Stock Positions Revealed! Technology stocks have once again become the first choice for “smart money”. Where are the market trends pointing?
Berkshire drastically reduced its Apple holdings by 116 million shares in the first quarter, and its share of holdings fell to 41%; the biggest increase in Tiger Global Fund's holdings was Google, which increased its holdings by 154.1%; among Qiaoshui's holdings, Pinduoduo and NIO reduced their holdings by 36.61% and 48.05%.
Eli Lilly's QWINT-2 And QWINT-4 Phase 3 Trials Of Once-weekly Insulin Efsitora In Type 2 Diabetes Patients Using Insulin For First Time And Require Multiple Daily Injections, Efsitora Showed Non-Inferior A1C Reduction Vs. Most Commonly Used Daily Insulin
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetesEfsitora was equally safe and effective among adults naïve to insul
Duquesne Family Office Top Q1 Buys, Cuts: Coherent, Eli Lilly, Others
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.